Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR1D | P28221 | 9/20 | 0.61 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121913 | 0.89 | NOS3 (0.53) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL216229 | 0.87 | HTR2C (0.61) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL30411128 | 0.87 | HTR2C (0.61) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL8648989 | 0.81 | EGFR (0.48) | HTR2CHTR2AHTR1DHTR6 | |
| SCHEMBL27400363 | 0.81 | HTR2C (0.61) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL23956080 | 0.81 | HTR2C (0.69) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL7252922 | 0.81 | HTR2A (0.64) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL31258100 | 0.81 | HTR2A (0.64) | HTR2CHTR2AHTR1DNOS3NOS1 | |
| SCHEMBL29780573 | 0.80 | KMO (0.44) | HTR2CHTR2AHTR1DHTR6 | |
| SCHEMBL23413236 | 0.80 | KMO (0.44) | HTR2CHTR2AHTR1DHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456602-A | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2017-02-22 | — | — | CN | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| EP-0760665-B1 | COMPOSITIONS CONTAINING 5HTIA AND 5HTID ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-12-12 | — | — | EP | disclosed |
| EP-0902027-B1 | Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them | ADIR (FR) | 2001-07-25 | — | — | EP | disclosed |
| US-6046205-A | FOR TREATMENT OF VENOUS INSUFFICIENCY AND OF ASSOCIATED DISORDERS, AND ALSO IN THE TREATMENT OF MIGRAINE | ADIR ET COMPAGNIE (FR) | 2000-04-04 | — | — | US | disclosed |
| US-6020336-A | Indole and indazole compounds | LES LABORATOIRES SERVIER (FR) | 2000-02-01 | — | — | US | disclosed |
| EP-0902027-A1 | Indole and indazole derivatives, process for their preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-03-17 | — | — | EP | disclosed |
| US-5756496-A | Amide derivatives having 5HT1D-antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-05-26 | — | — | US | disclosed |
| EP-0763034-A1 | AMIDE DERIVATIVES HAVING 5HT1D-ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0757686-A1 | BENZOFURAN DERIVATIVES AS D 4? RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995032967-A1 | AMIDE DERIVATIVES HAVING 5HT1D-ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-12-07 | — | — | WO | disclosed |
| WO-1995029911-A1 | BENZOFURAN DERIVATIVES AS D4 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR2C 434/4885HTR2A 156/4885HTR1D 511/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR2C 23/4885HTR2A 18/4885HTR1D 50/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR2C 434/4885HTR2A 156/4885HTR1D 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.